• Mashup Score: 1

    The FDA announced that it has designated a recall of blood tests for cardiac troponin shown to produce false negatives for MI as class I, the most serious kind.On May 25, Quidel Cardiovascular Inc. recalled its cardiac panels (Quidel Triage Cardiac Panel; Quidel Triage Cardiac Panel, Troponin I; and Quidel Triage Cardiac Panel, CK-MB and Troponin I) after it received reports of inaccurate tests

    Tweet Tweets with this article
    • #ICYMI: The #FDA has designated a recall of certain #blood tests for cardiac #troponin due to the risk for false negative or falsely low levels, which can result in missed or delayed #MI diagnoses. https://t.co/wmKEyu4Qlz

  • Mashup Score: 0

    Objective Beta-blockers (BB) are an established treatment following myocardial infarction (MI). However, there is uncertainty as to whether BB beyond the first year of MI have a role in patients without heart failure or left ventricular systolic dysfunction (LVSD). Methods A nationwide cohort study was conducted including 43 618 patients with MI between 2005 and 2016 in the Swedish register for…

    Tweet Tweets with this article
    • Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes https://t.co/rk7sWDngfG #bblocker #MI #cardiotwitter via @Heart_BMJ